Oxitec was formed in 2002 by Oxford University Innovation and, in 2015, was acquired by U.S.-based Intrexon.
Since inception, Oxitec has pioneered work on controlling insects that spread disease and damage crops through world-class genetic engineering and the use of self-limiting gene technology. In the mid and late 2000s, Oxitec successfully deployed genetically engineered insects in select locations in the USA, Caribbean, South America, and has continued to grow these projects, expanding to new regions and countries.
In 2016, the World Health Organization (WHO) issued a positive recommendation in support of Oxitec’s self-limiting mosquitoes (OX513A) for a planned pilot in response to the Zika virus outbreak. Oxitec continues to engage with communities around the world that are in need of effective, scalable solutions to combat the dangerous vectors that threaten lives and livelihoods.
Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems.
Where is Oxitec